682 related articles for article (PubMed ID: 9481250)
1. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
Gale DM; Kiley KE
Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250
[TBL] [Abstract][Full Text] [Related]
2. High-dose adjuvant interferon therapy for melanoma.
Licata AG
Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
[TBL] [Abstract][Full Text] [Related]
4. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
5. Current therapy of cutaneous melanoma.
Mays SR; Nelson BR
Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
[TBL] [Abstract][Full Text] [Related]
6. Update on the role of adjuvant interferon for high risk melanoma.
Agarwala SS; Kirkwood JM
Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
Kirkwood JM; Tarhini AA
Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
[TBL] [Abstract][Full Text] [Related]
8. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant interferon therapy for melanoma.
Hancock B; Wheatley K; Ives N; Gore M
J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
[No Abstract] [Full Text] [Related]
10. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
Bajetta E
Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
[No Abstract] [Full Text] [Related]
11. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
12. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
Agarwala SS; Gray RJ; Wong MK
J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
[No Abstract] [Full Text] [Related]
13. Update on adjuvant interferon therapy for high-risk melanoma.
Agarwala SS; Kirkwood JM
Oncology (Williston Park); 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197. PubMed ID: 12380946
[TBL] [Abstract][Full Text] [Related]
14. [Interferons and malignant melanoma].
Dreno B
Rev Med Interne; 2002 Nov; 23 Suppl 4():489s-493s. PubMed ID: 12481404
[TBL] [Abstract][Full Text] [Related]
15. [Current therapy of carcinoma of the skin].
Dummer R; Goldinger SM; Sailer E; French LE
Ther Umsch; 2010 Sep; 67(9):447-52. PubMed ID: 20806173
[TBL] [Abstract][Full Text] [Related]
16. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma.
Dubois RW; Swetter SM; Atkins M; McMasters K; Halbert R; Miller SJ; Shiell R; Kirkwood J
Arch Dermatol; 2001 Sep; 137(9):1217-24. PubMed ID: 11559220
[TBL] [Abstract][Full Text] [Related]
17. Who benefits most from adjuvant interferon treatment for melanoma?
Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
[TBL] [Abstract][Full Text] [Related]
18. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
Kimyai-Asadi A; Usman A
J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
[TBL] [Abstract][Full Text] [Related]
19. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.
Rusciani L; Proietti I; Paradisi A; Rusciani A; Guerriero G; Mammone A; De Gaetano A; Lippa S
Melanoma Res; 2007 Jun; 17(3):177-83. PubMed ID: 17505263
[TBL] [Abstract][Full Text] [Related]
20. How does interferon work? Does it even matter?
Sondak VK
Cancer; 2002 Sep; 95(5):947-9. PubMed ID: 12209676
[No Abstract] [Full Text] [Related]
[Next] [New Search]
